[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","mrg34vdb21oasf4ssqwpbbhie","revision",2,"title","Bio Essence Corp 董事会成员变更及章程修订","originalTitle","Bio Essence Corp (0001723059) (Filer)","summary","Bio Essence Corp 董事会新增 Thea Zhang 和 Geoff Fellows 两位董事。公司修订章程取消董事人数上限，从最多3人增至10人。该修订于2026年10月19日由股东投票通过。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-23T19:43:41.000Z","discoveredAt","2026-10-23T19:53:27.983Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",29,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fVpYvCs7uuK8",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","574da984-4dbf-45c9-bdb7-3e647c30ca5a","Bio Essence Corp 董事会变动及章程修订",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 15, 2026

(Date of Report)

BIO ESSENCE CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

\n \n \n \n \n \n \n \n \n \n \n \n \n

California

000-56263

94-3349551

(STATE OR OTHER JURISDICTION OF

INCORPORATION OR ORGANIZATION)

(COMMISSION FILE NO.)

(IRS EMPLOYEE
\nIDENTIFICATION NO.)

2955 Main Street, Suite 300, Irvine, CA 92618
\n(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(949) 706-9966
\n(ISSUER TELEPHONE NUMBER)

Check the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):

\n \n \n \n

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n \n \n \n

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n \n \n \n

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n \n \n \n

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)\nof the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the\nregistrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or\nRule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒

If an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of\nDirectors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers

On October 19, 2026, a majority of shareholders\nof Bio Essence Corp., a California corporation (“Company”) elected by way of written consent Thea Zhang and Geoff Fellows\nas a Directors of the Company.

Ms. Zhang is a strategic business and operations\nleader with more than fifteen years of experience overseeing business operations, manufacturing strategy, and product commercialization.\nShe previously worked for Spyglass Pharma, Inc., as a Senior Manager, and Oasis Medical, Inc., in the same role. Ms. Zhang received a\nMaster’s Degree in Business Administration from the University of Toledo, and a Bachelor’s Degree in Engineering – Pharmaceutical\nScience from Nanjing University of Technology in Nanjing, China.

Mr. Fellows similarly has experience as a business leader, with years of experience in the industry. He is the chief executive officer\nof Embarcadero Accessible Multi-Family Office, where he has historically overseen the firm’s tax and legal departments. Mr. Fellows\nbrings more than three decades of experience in finance, operations, compliance, and governance from across the financial services industry\nto the Board.

Ms. Zhang and Mr. Fellows have no arrangement\nor understanding regarding their appointment, nor are they a party to any material plan, contract, or arrangement, and no transactions\ndisclosable pursuant to Item 404(a) of Regulation S-K.

Item 5.03 Amendments to Articles of Incorporation\nor Bylaws; Change of Fiscal Year

On October 19, 2026, a majority of shareholders\nof the Company voted to modify the Bylaws of the Company to remove the limit on the number of Directors that could be elected to the Board\nof Directors. Under the original Bylaws, the Company could have between one and three Directors. The new Amendment, memorialized in the\nConsent attached here, changes the limit from three Directors to ten directors. No other revisions were made to the Bylaws.

SIGNATURES

Pursuant to the requirements\nof the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	BIO ESSENCE CORP.

	/s/ Yin Yan
	By:	Yin Yan
	Its:	Chief Executive Officer
	Dated: October 23, 2026

","zhKind","complete","BIOE","政策与监管","退市","停复牌","aihot","/items/mrg34vdb21oasf4ssqwpbbhie","https://www.sec.gov/Archives/edgar/data/1723059/000121390026112075/0001213900-26-112075-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792972800&sig=9d173b888aad17ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792972800&sig=997f44534d647b46 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792972800&sig=923979fb4a1845f5 96w","changelogVersion","2026-10-01T08:00"]